open access

Vol 67, No 4 (2016)
Original papers
Published online: 2016-07-05
Submitted: 2015-10-18
Accepted: 2016-05-11
Get Citation

Diagnostics of SHOX gene rearrangement in 46,XX women with idiopathic short stature

Magdalena Mitka, Michał Bednarek, Bogdan Kałużewski
DOI: 10.5603/EP.a2016.0050
·
Endokrynologia Polska 2016;67(4):397-402.

open access

Vol 67, No 4 (2016)
Original papers
Published online: 2016-07-05
Submitted: 2015-10-18
Accepted: 2016-05-11

Abstract

Introduction: The SHOX gene has been mapped at the pseudoautosomal region 1 (PAR1) of chromosomes X (Xp22.33) and Y (Yp11.32). The loss of SHOX gene functionality is assumed to be responsible for the Leri-Weill syndrome formation and the disproportionate short stature (DSS). The SHOX gene rearrangements constitute the majority of cases of gene functionality loss. Therefore, a practical application of the method, which allows for the diagnostics of the gene rearrangements, becomes a primary issue. With such an assumption, the MLPA technique (multiplex ligation — dependent probe amplification) becomes the method of choice.

Material and methods: DNA samples were evaluated in the study by means of the MLPA method. The DNA was isolated from peripheral blood of sixty-three (63) 46,XX patients with short stature.

Results: Out of the examined patients, deletions within the SHOX gene were found in five (5) patients, and duplication at the PAR1 regulatory region of the SHOX gene in one (1) case.

Conclusions: The obtained results confirm the opinion that the MLPA method, while enabling the diagnostics of the etiopathogenetic factor of short stature, identified in approximately 9.5% of cases, is a useful tool in the diagnostics of SHOX gene deletion and duplication. (Endokrynol Pol 2016; 67 (4): 397–402)

Abstract

Introduction: The SHOX gene has been mapped at the pseudoautosomal region 1 (PAR1) of chromosomes X (Xp22.33) and Y (Yp11.32). The loss of SHOX gene functionality is assumed to be responsible for the Leri-Weill syndrome formation and the disproportionate short stature (DSS). The SHOX gene rearrangements constitute the majority of cases of gene functionality loss. Therefore, a practical application of the method, which allows for the diagnostics of the gene rearrangements, becomes a primary issue. With such an assumption, the MLPA technique (multiplex ligation — dependent probe amplification) becomes the method of choice.

Material and methods: DNA samples were evaluated in the study by means of the MLPA method. The DNA was isolated from peripheral blood of sixty-three (63) 46,XX patients with short stature.

Results: Out of the examined patients, deletions within the SHOX gene were found in five (5) patients, and duplication at the PAR1 regulatory region of the SHOX gene in one (1) case.

Conclusions: The obtained results confirm the opinion that the MLPA method, while enabling the diagnostics of the etiopathogenetic factor of short stature, identified in approximately 9.5% of cases, is a useful tool in the diagnostics of SHOX gene deletion and duplication. (Endokrynol Pol 2016; 67 (4): 397–402)

Get Citation

Keywords

short stature; MLPA; SHOX

About this article
Title

Diagnostics of SHOX gene rearrangement in 46,XX women with idiopathic short stature

Journal

Endokrynologia Polska

Issue

Vol 67, No 4 (2016)

Pages

397-402

Published online

2016-07-05

DOI

10.5603/EP.a2016.0050

Bibliographic record

Endokrynologia Polska 2016;67(4):397-402.

Keywords

short stature
MLPA
SHOX

Authors

Magdalena Mitka
Michał Bednarek
Bogdan Kałużewski

Important: This website uses cookies.tanya dokter More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Via MedicaWydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl